Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Adjuvant treatment
CTNNB1
Endometrioid
Risk group
β-Catenin
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
24
02
2021
accepted:
20
12
2021
pubmed:
17
1
2022
medline:
6
8
2022
entrez:
16
1
2022
Statut:
ppublish
Résumé
In the last years, mutations in the exon 3 of CTNNB1 have emerged as a possible prognostic factor for recurrence in early stage endometrioid endometrial carcinoma, especially in cases with no specific molecular profile (NSMP). To define the prognostic value of CTNNB1 mutations in early stage endometrioid endometrial carcinoma, through a systematic review and meta-analysis. Electronic databases were searched from their inception to November 2020 for all studies assessing the prognostic value of CTNNB1 mutation in early stage (FIGO I-II) endometrioid endometrial carcinoma. Odds ratio (OR) for tumor recurrence and hazard ratio (HR) for disease-free survival (DFS) were calculated with a significant p value < 0.05. Seven studies with 1031 patients were included. Four studies were suitable for meta-analysis of OR and showed significant association between CTNNB1 mutation and the absolute number of recurrence (OR = 3.000; p = 0.019); the association became stronger after excluding patients with known molecular status other than NSMP (HR = 5.953; p = 0.012). Three studies were suitable for meta-analysis of HR and showed no significant association between CTNNB1 mutation and decreased DFS (HR = 1.847; p = 0.303); the association became significant after excluding patients with known molecular status other than NSMP (HR = 2.831; p = 0.026). CTNNB1 mutation is significantly associated with recurrence in early stage endometrioid endometrial carcinomas, especially in the NSMP, appearing potentially useful in directing adjuvant treatment.
Sections du résumé
BACKGROUND
In the last years, mutations in the exon 3 of CTNNB1 have emerged as a possible prognostic factor for recurrence in early stage endometrioid endometrial carcinoma, especially in cases with no specific molecular profile (NSMP).
OBJECTIVE
To define the prognostic value of CTNNB1 mutations in early stage endometrioid endometrial carcinoma, through a systematic review and meta-analysis.
METHODS
Electronic databases were searched from their inception to November 2020 for all studies assessing the prognostic value of CTNNB1 mutation in early stage (FIGO I-II) endometrioid endometrial carcinoma. Odds ratio (OR) for tumor recurrence and hazard ratio (HR) for disease-free survival (DFS) were calculated with a significant p value < 0.05.
RESULTS
Seven studies with 1031 patients were included. Four studies were suitable for meta-analysis of OR and showed significant association between CTNNB1 mutation and the absolute number of recurrence (OR = 3.000; p = 0.019); the association became stronger after excluding patients with known molecular status other than NSMP (HR = 5.953; p = 0.012). Three studies were suitable for meta-analysis of HR and showed no significant association between CTNNB1 mutation and decreased DFS (HR = 1.847; p = 0.303); the association became significant after excluding patients with known molecular status other than NSMP (HR = 2.831; p = 0.026).
CONCLUSION
CTNNB1 mutation is significantly associated with recurrence in early stage endometrioid endometrial carcinomas, especially in the NSMP, appearing potentially useful in directing adjuvant treatment.
Identifiants
pubmed: 35034160
doi: 10.1007/s00404-021-06385-0
pii: 10.1007/s00404-021-06385-0
pmc: PMC9349085
doi:
Substances chimiques
Biomarkers, Tumor
0
CTNNB1 protein, human
0
beta Catenin
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
423-431Informations de copyright
© 2022. The Author(s).
Références
Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:478-483
pubmed: 33189427
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Mod Pathol. 2021 Jan;34(1):222-232
pubmed: 32728223
J Pathol. 2017 Oct;243(2):230-241
pubmed: 28718916
Gynecol Oncol. 2014 Aug;134(2):426-7
pubmed: 24952365
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
Radiother Oncol. 2021 Feb;155:160-166
pubmed: 33159971
Am J Surg Pathol. 2020 Feb;44(2):174-181
pubmed: 31651527
Cancer. 2000 May 15;88(10):2290-7
pubmed: 10820351
APMIS. 2019 Nov;127(11):699-709
pubmed: 31403731
Gynecol Oncol. 2014 Feb;132(2):351-9
pubmed: 24378878
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Gynecol Oncol. 2021 Feb;160(2):579-585
pubmed: 33276986
Cell Biosci. 2020 Oct 22;10:122
pubmed: 33110489
Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007
pubmed: 33046573
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Am J Surg Pathol. 2020 May;44(5):641-648
pubmed: 32205482
Clin Cancer Res. 2004 May 1;10(9):3098-103
pubmed: 15131049
Pathol Oncol Res. 2020 Jul;26(3):1417-1427
pubmed: 32377987
Mod Pathol. 2018 Oct;31(10):1553-1559
pubmed: 29795437
Gynecol Oncol. 2019 Jun;153(3):517-520
pubmed: 30910249
Ann Oncol. 2016 Apr;27(4):625-34
pubmed: 26782955
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Am J Clin Pathol. 2019 Apr 2;151(5):529-538
pubmed: 30715091
Gynecol Oncol. 2020 Apr;157(1):252-259
pubmed: 31932106
Acta Obstet Gynecol Scand. 2020 Feb;99(2):196-203
pubmed: 31562818
Int J Gynecol Cancer. 2020 Jun;30(6):717-723
pubmed: 32376737
PLoS One. 2013;8(3):e60145
pubmed: 23555905
Pathol Oncol Res. 2020 Jul;26(3):1411-1416
pubmed: 31811476
Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):646-653
pubmed: 31855579
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Gynecol Oncol. 2019 Jun;153(3):487-495
pubmed: 30922603
Gynecol Oncol. 2019 Nov;155(2):374-383
pubmed: 31472940
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2021 Nov;163(2):427-432
pubmed: 34446267
Arch Gynecol Obstet. 2020 Jun;301(6):1355-1363
pubmed: 32296930
Gynecol Oncol. 2020 Jul;158(1):3-11
pubmed: 32331700
Mod Pathol. 2017 Jul;30(7):1032-1041
pubmed: 28281553
Gynecol Oncol. 2018 Jan;148(1):174-180
pubmed: 29132872
Am J Surg Pathol. 2018 May;42(5):561-568
pubmed: 29505428
Am J Surg Pathol. 2021 Mar 1;45(3):421-429
pubmed: 33021522
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Pathol Res Pract. 2020 Aug;216(8):153025
pubmed: 32703491
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Gynecol Oncol. 2018 Oct;151(1):69-75
pubmed: 30078506